Female Health FHCO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Female Health FHCO

VERU 2.600

-11.9%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	2/1/2022 9:58:15 AM
	of 211

Veru Inc. said the U.S. Food and Drug Administration has granted fast track designation to the Phase 3 registration program for the investigation of sabizabulin to fight Covid-19 infection and the cytokine storm that is responsible for Acute Respiratory Distress Syndrome and death. FDA fast track designation is intended to expedite the development and review of new drugs to treat serious medical conditions that fill unmet medical needs. "We are very pleased that the sabizabulin therapeutic for Covid-19 clinical program has received fast track designation from the FDA, a distinction that underscores the urgent need for new, novel, effective therapies to be used along with vaccinations to combat this Covid-19 pandemic," said Mitchell Steiner, chief executive of Veru. Veru shares were up 4% to $4.92 in premarket trading. Jan 31

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next